Journals / Türkiye Çocuk Hastalıkları Dergisi / 2019 / Cilt: 13 - Sayı: 5

Evaluation of the Clinical Characteristics of the Girls with Central Precocious Puberty at Diagnosis and During Treatment

Pages
358–362
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Awareness level of primary care physicians and pediatricians should be increased in order to identify the early puberty findings and provide appropriate guidance.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: It is aimed to evaluate the anthropometric and clinical characteristics of the girls with idiopathic central precocius puberty (CPP) at diagnosis, during and at the end of treatment.
📊
Key Findings & Data:Materials and methods: Sixty-one girls who were diagnosed with CPP and treated between January 2015 and December 2018 were included in the study.
💡
Conclusion & Impact:Awareness level of primary care physicians and pediatricians should be increased in order to identify the early puberty findings and provide appropriate guidance.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Awareness · idiopathic · menarche

Özet

Aim: It is aimed to evaluate the anthropometric and clinical characteristics of the girls with idiopathic central precocius puberty (CPP) at diagnosis, during and at the end of treatment. Materials and methods: Sixty-one girls who were diagnosed with CPP and treated between January 2015 and December 2018 were included in the study. The anthropometric, clinical characteristics and laboratory test results at diagnosis, during and at the end of treatment were retrospectively evaluated. Results: Mean age of the patients at diagnosis was 8.7±0.6 years, bone age was 10.3±1.3 years, target height was 158.4±5.2 cm and predicted height was 160.1±7.6 cm. While 18 (30%) patients presented with isolated thelarche, 11 (18%) patients presented with menarche. At diagnosis, 28% of the patients were obese and 25% were overweight. The average treatment period was 2 years. The body mass index (BMI) increased during treatment (p<0.001) which was significant especially in the first two years of treatment (p<0.001). In first year of treatment, the ratio of the obese patients had increased to 36%. During treatment, height growth rates were decreased (p=0.02). However, the predicted height at the end of the study was 160.1±6.2 cm and there was no difference when compared to the height at diagnosis (p>0.05). Conclusion: Obese and overweight girls should be followed up for pubertal development. Awareness level of primary care physicians and pediatricians should be increased in order to identify the early puberty findings and provide appropriate guidance.

🔖

Cite This Article

KARA, Ö. (2022). Evaluation of the Clinical Characteristics of the Girls with Central Precocious Puberty at Diagnosis and During Treatment. Türkiye Çocuk Hastalıkları Dergisi, Cilt: 13 - Sayı: 5, 358–362. https://ajindex.com/articles/627146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Sorensen K, Mouritsen A, Aksglaede L, Hagen CP, et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012;77(3):137-4
  2. Teilmann G, Pedersen CB, Jensen TK, et al. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005 Dec;116(6):1323-8
  3. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370–372
  4. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159(6):982-7
  5. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Anologs Consensus Conference Group. Consensus statement on the use of gonodotropin-releasing hormone analogs in the children. Pediatrics 2009;123:e752-62 6. Cassio A, Bal MO, Orsini LF, et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr. 2006 Oct;149(4):532-6 7. Assa A, Weiss M, Aharoni D, et al. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist. J Pediatr Endocrinol Metab. 2011;24(7-8):505-10
  6. Cruz JNZ, Rodríguez ID, NishimuraMeguro E et al. Change in body mass index among girls with precocious puberty under treatment. Arch Argent Pediatr 2016;114(2):143-146
  7. Chiocca E, Dati E, Baroncelli GI et al. Body Mass Index and Body Composition in Adolescents Treated with Gonadotropin-Releasing Hormone Analogue Triptorelin Depot for Central Precocious Puberty: Data at Near Final Height. Neuroendocrinology 2009;89:441–447
  8. Pasquino AM, Pucarelli I, Accardo F et al. Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function. J Clin Endocrinol Metab. January 2008, 93(1):190–195
  9. Palmert MR, Mansfield MJ, Crowley WF, et al. Is Obesity an Outcome of Gonadotropin-Releasing Hormone Agonist Administration? Analysis of Growth and Body Composition in 110 Patients with Central Precocious Puberty. J Clin Endocrinol Metab. 1999 Dec;84(12):4480-8
  10. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, et al. Reducti